The pharmaceutical industry is navigating one of the most complex and consequential shifts in its history. The environment for launching new products has changed dramatically, and the legacy model – once the cornerstone of commercial success – is increasingly misaligned with the realities of today’s healthcare ecosystem.

Historically, drug launches followed a predictable path: build a robust sales force, train them to deliver product messaging, and deploy them to physicians’ offices to build relationships and drive prescribing behavior. This “feet on the street” model was supported by a commercial infrastructure designed to reinforce physician engagement, with brand teams, marketing, and sales operations all aligned around the prescriber as the primary decision-maker.

But that model is increasingly out of step with market realities. Hospitals and integrated delivery networks (IDNs) have implemented policies that restrict direct access to physicians. Increasingly, decisions about drug adoption are made by administrative committees and C-suite executives focused on system-wide priorities like cost containment, clinical outcomes, and population health. The consolidation of health systems has accelerated this trend, centralizing decision-making across networks and reducing the autonomy of individual facilities. What was once a fragmented landscape of independent hospitals and practices is now a tightly controlled matrix of centralized governance.